Procept Biorobotics CORP 8-K filings

PROCEPT BioRobotics Corporation shareholders elected three directors and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Procept Biorobotics reported a 20% increase in first-quarter revenue to $83.1 million, driven by strong U.S. system sales and improved pricing, alongside a 30% rise in U.S. procedures.

PROCEPT BioRobotics outlines strong financial growth, margin expansion, and a clear path to profitability by 2027, alongside strategic expansion into the prostate cancer market.

PROCEPT BioRobotics reported strong Q4 2025 procedure volume and system sales, alongside a reset of 2026 revenue guidance due to strategic realignments.

PROCEPT BioRobotics Corporation announced robust third-quarter 2025 financial results, with total revenue increasing 43% year-over-year and issued optimistic 2026 revenue guidance.

PROCEPT BioRobotics Corporation's Compensation Committee approved amendments to executive Change of Control and Severance Agreements, enhancing benefits for non-CEO officers.

PROCEPT BioRobotics reported strong second-quarter 2025 financial results, with total revenue increasing 48% year-over-year and an upward revision of its full-year 2025 revenue guidance.

PROCEPT BioRobotics announced the appointment of Larry L. Wood as its new President and CEO, effective September 2, 2025, succeeding retiring Dr. Reza Zadno, and pre-announced robust second-quarter 2025 revenue of approximately $79.2 million, marking a 48% annual increase.

PROCEPT BioRobotics Corporation announced the successful election of all director nominees, the ratification of PricewaterhouseCoopers LLP as its independent auditor, and the advisory approval of executive compensation at its annual stockholders' meeting on June 10, 2025.

PROCEPT BioRobotics highlights its prostate cancer initiative and presents clinical data, including updates on the WATER IV trial and early data from PRCT001 and PRCT002, at the American Urological Association (AUA) Annual Meeting.

PROCEPT BioRobotics announced a 55% increase in first-quarter revenue and raised its full-year 2025 revenue guidance to $323 million.

PROCEPT BioRobotics announces a 57% increase in fourth-quarter revenue and issues a promising 2025 revenue guidance of approximately $320 million.

PROCEPT BioRobotics Corporation successfully closed a public offering of common stock, generating net proceeds of approximately $163.8 million.

PROCEPT BioRobotics reported a 66% increase in revenue for the third quarter of 2024, driven by strong U.S. and international sales, and raised its full-year revenue and adjusted EBITDA guidance.

PROCEPT BioRobotics Corporation announced that the FDA has granted 510(k) clearance for its HYDROS Robotic System, a next-generation platform for Aquablation therapy.

PROCEPT BioRobotics announced a 61% increase in revenue for the second quarter of 2024 and raised its full-year revenue and EBITDA guidance.

PROCEPT BioRobotics Corporation has announced the resignation of a director and the appointment of a new director and chairperson, effective July 18, 2024.

PROCEPT BioRobotics Corporation held its annual meeting on June 4, 2024, where directors were elected, the accounting firm was ratified, and executive compensation was approved.

PROCEPT BioRobotics is experiencing significant revenue growth and is expanding its focus to include prostate cancer treatment using its Aquablation technology.

PROCEPT BioRobotics announced a significant 83% increase in first-quarter revenue and raised its full-year revenue guidance to $213.5 million.

PROCEPT BioRobotics Corporation has announced the resignation of director Colby Wood and the appointment of Larry Wood to its board, effective April 18, 2024.

PROCEPT BioRobotics announced an 82% increase in full-year 2023 revenue and provided a 2024 revenue guidance of approximately $210 million.